Spots Global Cancer Trial Database for A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma
Official Title: A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination With Gemcitabine in Adult and Pediatric Subjects With Relapsed or Refractory Osteosarcoma
Study ID: NCT04833582
Conditions
Study Description
Brief Summary: This is a phase 1/2 study of ZN-c3 in combination with gemcitabine in adult and pediatric subjects with relapsed or refractory osteosarcoma.
Detailed Description: This is a phase 1/2 dose escalation and dose expansion study, evaluating the clinical activity and safety, pharmacodynamics, and pharmacokinetics of ZN-c3 in combination with gemcitabine in relapsed or refractory osteosarcoma.
Keywords
Eligibility
Minimum Age: 12 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Site 0106, Los Angeles, California, United States
Site 0124, Oakland, California, United States
Site 0195, Santa Monica, California, United States
University of Florida College of Medicine, Gainesville, Florida, United States
Site 0105, New York, New York, United States
Site 0107, Cincinnati, Ohio, United States
Site 0123, Portland, Oregon, United States
Site 0193, Memphis, Tennessee, United States
Site 0197, Nashville, Tennessee, United States
Site 0103, Houston, Texas, United States
Site 0188, Richmond, Virginia, United States
Site 0122, Seattle, Washington, United States
Site 3604, Bordeaux, , France
Site 3601, Lyon, , France
Site 3602, Marseille, , France
Site 3606, Paris, , France
Site 3605, Toulouse, , France
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
